Skip to main content
PepStack
Wiki · Profile

PT-141

Bremelanotide · Vyleesi

Sexual HealthPhase III
From$2.10/mgCompare prices
MW
1025.2g/mol
Formula
C50H68N14O10

PT-141 is a cyclic heptapeptide and a synthetic analog of the melanocortin peptide, originally derived from the natural peptide PT-14. Researchers primarily study PT-141 for its potential applications in addressing erectile dysfunction (ED) and female sexual dysfunction. Key findings from clinical studies indicate that PT-141 can enhance erectile responses, particularly when co-administered with phosphodiesterase type 5 inhibitors like sildenafil, and it has shown significant efficacy in patients who do not respond adequately to standard treatments. Current research status includes ongoing phase III clinical trials aimed at further evaluating its safety and effectiveness in diverse patient populations.

Chemical Profile

Chemical Profile

Chemical structure
Chemical Structure
FormulaC50H68N14O10
Molecular Weight1025.2 g/mol
CAS Number189691-06-3
PubChem CID9941379
ChEMBL IDCHEMBL5315036

Half-Life

SCSubcutaneous

~2 to 4 hours

INIntranasal

Not applicable

POOral

Poor bioavailability

The pharmacokinetic profile is characterized by rapid absorption and onset of action when administered subcutaneously.

Mechanism

Mechanism of Action

PT-141 acts as an agonist of melanocortin receptors (MCRs), particularly the MC3R and MC4R subtypes, which are involved in the regulation of sexual arousal and erectile function. The activation of these receptors stimulates intracellular signaling pathways, including the activation of adenylate cyclase, leading to increased cyclic AMP (cAMP) levels, which enhances vasodilation and blood flow to the genital area. Although the precise mechanisms and downstream effects remain to be fully elucidated, PT-141's action on MCRs suggests a role in modulating neurovascular processes associated with sexual response.

Research

17 Research Publications

806

Total Citations

6

Human/RCT

3.3

Avg. Influence

2023

Latest

Sort
Filter
#01

Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.

AnimalInfluence5.0
123
Researchers observed that PT-141 selectively stimulates solicitational behaviors in female rats without affecting other sexual behaviors, suggesting its potential role in addressing female sexual desire disorders.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#02

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.

HumanInfluence3.0
119
Researchers observed that intranasal PT-141 administration resulted in a significant erectile response in healthy males and Viagra-responsive patients, with a favorable pharmacokinetic profile and tolerability.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#03

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Human
113
Researchers observed that bremelanotide (PT-141) positively affected sexual desire and arousal in premenopausal women with sexual arousal disorder, indicating its potential for further evaluation.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#04

PT-141: a melanocortin agonist for the treatment of sexual dysfunction.

HumanInfluence8.0
105
The study demonstrated that PT-141, a melanocortin receptor agonist, induces a rapid, dose-dependent increase in erectile activity in both rats and humans.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#05

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

HumanInfluence2.0
90
The study demonstrated that subcutaneous administration of PT-141 resulted in statistically significant erectile responses in both healthy males and patients with erectile dysfunction who inadequately responded to Viagra.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#06

Melanocortins in the treatment of male and female sexual dysfunction.

ReviewInfluence1.0
57
The study demonstrated that melanocortinergic agents, including PT-141, may provide therapeutic benefits for both male and female sexual dysfunction, supported by clinical data on their efficacy.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#07

Melanocortin receptors, melanotropic peptides and penile erection.

AnimalInfluence1.0
51
The study demonstrated that activation of melanocortin receptors may facilitate penile erection, with PT-141 showing potential as a centrally mediated therapeutic approach for erectile dysfunction.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#08

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

HumanInfluence3.0
44
Researchers observed that co-administration of intranasal PT-141 and sildenafil significantly enhanced erectile response in men with erectile dysfunction compared to sildenafil alone, with a favorable safety profile.
7.5 mgintranasal(human)4 mgsubcutaneous(human)6 mgsubcutaneous(human)20 mgintranasal(human)
PubMed
#09

Medical Treatment of Female Sexual Dysfunction.

Nappi Rossella E, et al. · The Urologic clinics of North America · 2022

Review
33
Researchers reviewed various treatments for female sexual dysfunction (FSD), which involves multiple overlapping disorders influenced by biological, psychological, and social factors. They found that healthcare providers can screen for FSD and offer initial counseling before referring patients to specialists, with a range of treatment options available for different stages of life.

Key findings

  1. 01Researchers observed that flibanserin and bremelanotide are effective for premenopausal women with low sexual desire.
  2. 02Transdermal testosterone was noted to be effective for postmenopausal women experiencing similar issues.
  3. 03The study highlighted that menopause hormone therapy is crucial for managing symptoms in women during midlife.
PubMed
#10

Bremelanotide for Treatment of Female Hypoactive Sexual Desire.

Edinoff Amber N, et al. · Neurology international · 2022

Review
24
Researchers studied bremelanotide, a new treatment for women with hypoactive sexual desire disorder (HSDD), which causes a significant lack of sexual desire and distress. The study found that bremelanotide improved sexual desire, arousal, and orgasm scores when used before sexual activity compared to a placebo.

Key findings

  1. 01Bremelanotide was recently approved by the FDA for treating HSDD in women.
  2. 02Researchers observed improvements in sexual desire and arousal after using bremelanotide.
  3. 03The treatment targets both biological and psychosocial factors related to HSDD.
PubMed
Safety

Safety & Handling

Research Gaps

No long-term safety and efficacy data from large-scale human trials have been published for PT-141, particularly regarding its use in combination with other erectile dysfunction treatments. Additionally, the precise mechanisms by which PT-141 exerts its effects on sexual functionality and its potential impact on hormonal pathways remain unclear and require further investigation.

Solubility

PT-141 is soluble in water and DMSO, with limited solubility in organic solvents like acetonitrile.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Approved by the FDA for treatment of HSDD in premenopausal women. Not scheduled by the DEA.

🇦🇺AU

Data limited

🇬🇧UK

Data limited

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

15 total
2
03
5
04
2
05
2
06
2
07
1
25
1
26
Pricing

Price Comparison

  • BESTPeptiLab USAUS
    10mg
    $20.99
    Price/mg
    $2.10/mg
    View
  • XL PeptidesUK
    10mg
    $21.58
    Price/mg
    $2.16/mg
    View
  • RetaOneLabsUS
    10mg
    $24.00
    Price/mg
    $2.40/mg
    View
  • NG PeptideUS
    10mg
    $24.99
    Price/mg
    $2.50/mg
    View
  • Sports Technology LabsUS
    10mg
    $25.99
    Price/mg
    $2.60/mg
    View

Top 5 of 58 offers from 54 vendors. Prices updated daily.

See all PT-141 prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for PT-141

Serum Level Visualizer

Visualize PT-141 serum levels over time

Mechanism

Related Peptides

Melanotan IMelanotan II

Track PT-141 in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer